{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:24:07Z","timestamp":1792610647286,"version":"4.5.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Nearly 30% of patients infected with carbapenem-resistant <jats:italic>Klebsiella pneumoniae<\/jats:italic> (CRKP) were previously shown to be coinfected with carbapenem-resistant <jats:italic>Pseudomonas aeruginosa<\/jats:italic> (CRPA) or <jats:italic>Acinetobacter baumannii<\/jats:italic> (CRAB). Infections caused by multiple carbapenem-resistant pathogens present significant challenge to infection control and therapeutic management. The study objective was to identify risk factors for acquisition of multiple carbapenem-resistant pathogens and associated outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A descriptive analysis of adults infected with either CRKP alone or coinfected with CRPA or CRAB was performed. Patient groups were compared on demographics, clinical characteristics, treatment, and outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>86 patients with CRKP monoinfection and 60 patients with coinfections were evaluated. Respiratory tract was the predominant infection site for coinfected patients involving mostly CRPA whereas urinary tract was the primary site for CRKP-only group. More coinfected patients were severely debilitated, had prior carbapenem exposure (37% vs 13%, p&amp;lt;0.001) and history of pneumonia in the past year (67% vs 41%, p&amp;lt;0.01). More coinfected patients required direct ICU admission (45% vs 27%, p=0.02) and had prolonged length of stay (median 15 vs 10 days, p&amp;lt;0.01) than the CRKP-only group but mortality rates (18% vs 16%) were similar.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CRKP coinfection with another carbapenem-resistant pathogen adds significant morbidity and healthcare burden overall. Empiric therapy with reliable activity against both CRKP and carbapenem-resistant <jats:italic>Pseudomonas aeruginosa<\/jats:italic> may be prudent for at risk patients with pneumonia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2023.1231740","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:14:31Z","timestamp":1697440471000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Risk factors and outcome associated with coinfection with carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumanii: a descriptive analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Anthony","family":"Sophonsri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Kelsom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nieberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Wong-Beringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa386","article-title":"Epidemiologic and microbiologic characteristics of hospitalized patients co-colonized with multiple species of carbapenem-resistant enterobacteriaceae in the United States","volume":"7","author":"Adediran","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1503\/cmaj.092129","article-title":"Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis","volume":"183","author":"Eom","year":"2011","journal-title":"CMAJ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.279.18.1452","article-title":"Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines","volume":"279","author":"Halm","year":"1998","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCAP)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. BioMed. Inform."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1001\/jama.2009.722","article-title":"Acid-suppressive medication use and the risk for hospital-acquired pneumonia","volume":"301","author":"Herzig","year":"2009","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/geront\/10.1_part_1.20","article-title":"Progress in development of the index of ADL","volume":"10","author":"Katz","year":"1970","journal-title":"Gerontologist"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1007\/s10620-009-0951-9","article-title":"Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications","volume":"54","author":"Kedika","year":"2009","journal-title":"Dig Dis. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1001\/jama.292.16.1955","article-title":"Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs","volume":"292","author":"Laheij","year":"2004","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.919414","article-title":"Predictors of Occurrence and 30-Day Mortality for Coinfection of Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Acinetobacter baumannii","volume":"12","author":"Lv","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3109\/00365548.2013.782614","article-title":"Co-colonization with carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii in intensive care unit patients","volume":"45","author":"Mammina","year":"2013","journal-title":"Scand. J. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ajic.2011.10.013","article-title":"\"Swimming in resistance\": Co-colonization with carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii or Pseudomonas aeruginosa","volume":"40","author":"Marchaim","year":"2012","journal-title":"Am. J. Infect. Control."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.ajic.2015.06.008","article-title":"Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections","volume":"43","author":"Ny","year":"2015","journal-title":"Am. J. Infect. Control."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193431","article-title":"Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections","volume":"13","author":"Palavutitotai","year":"2018","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jhin.2011.05.014","article-title":"Acquisition of extensive drug-resistant Pseudomonas aeruginosa among hospitalized patients: risk factors and resistance mechanisms to carbapenems","volume":"79","author":"Park","year":"2011","journal-title":"J. Hosp Infect."},{"key":"B15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.phrs.2008.09.016","article-title":"Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety","volume":"59","author":"Savarino","year":"2009","journal-title":"Pharmacol. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1086\/671270","article-title":"Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity","volume":"34","author":"Swaminathan","year":"2013","journal-title":"Infect. Control Hosp Epidemiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jmii.2017.08.015","article-title":"Risk factors for healthcare-associated infection caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"51","author":"Tsao","year":"2018","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1128\/AAC.01758-13","article-title":"A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant","volume":"58","author":"Voor in 't holt","year":"2014","journal-title":"Pseudomonas aeruginosa. Antimicrob. Agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1097\/00003246-200205000-00026","article-title":"Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity","volume":"30","author":"Zedtwitz-liebenstein","year":"2002","journal-title":"Crit. Care Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11096-017-0524-5","article-title":"The quick loss of carbapenem susceptibility in Pseudomonas aeruginosa at intensive care units","volume":"40","author":"Zou","year":"2018","journal-title":"Int. J. Clin. Pharm."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1231740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:14:34Z","timestamp":1697440474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1231740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":20,"alternative-id":["10.3389\/fcimb.2023.1231740"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1231740","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"article-number":"1231740"}}